{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,5]],"date-time":"2026-07-05T21:15:43Z","timestamp":1783286143807,"version":"3.54.6"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,7,5]]},"DOI":"10.7759\/cureus.112103","type":"journal-article","created":{"date-parts":[[2026,7,5]],"date-time":"2026-07-05T20:56:53Z","timestamp":1783285013000},"source":"Crossref","is-referenced-by-count":0,"title":["Identifying Predictors of Pathological Complete Response in Moroccan Patients With HER2-Positive Breast Cancer Treated With Neoadjuvant Therapy"],"prefix":"10.7759","author":[{"given":"Boutaina","family":"Atmane","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jihad","family":"El Afeya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Safae","family":"Toumi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanane","family":"Inrhaoun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachid","family":"Razine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hind","family":"Mrabti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hassan","family":"Errihani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21834","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray F","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, Jemal A. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024, 74:229-63. 10.3322\/caac.21834","journal-title":"CA Cancer J Clin"},{"key":"ref2","unstructured":"Registre des Cancers de la R\u00e9gion du Grand Casablanca 2018-2021. Accessed. 15 June 2026: https:\/\/www.contrelecancer.ma\/fr\/documents\/registre-des-cancers-de-la-region-du-grand-casab-4\/."},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21863","article-title":"Breast cancer statistics 2024","volume":"74","author":"Giaquinto AN","year":"2024","unstructured":"Giaquinto AN, Sung H, Newman LA, et al.. Breast cancer statistics 2024. CA Cancer J Clin. 2024, 74:477-95. 10.3322\/caac.21863","journal-title":"CA Cancer J Clin"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/j.breast.2021.07.009","article-title":"Patterns of care of breast cancer patients in Morocco-a study of variations in patient profile, tumour characteristics and standard of care over a decade","volume":"59","author":"Mrabti H","year":"2021","unstructured":"Mrabti H, Sauvaget C, Benider A, et al.. Patterns of care of breast cancer patients in Morocco-a study of variations in patient profile, tumour characteristics and standard of care over a decade. Breast. 2021, 59:193-202. 10.1016\/j.breast.2021.07.009","journal-title":"Breast"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1186\/s12905-016-0361-z","article-title":"First report on molecular breast cancer subtypes and their clinico-pathological characteristics in Eastern Morocco: series of 2260 cases","volume":"17","author":"Elidrissi Errahhali M","year":"2017","unstructured":"Elidrissi Errahhali M, Elidrissi Errahhali M, Ouarzane M, El Harroudi T, Afqir S, Bellaoui M. First report on molecular breast cancer subtypes and their clinico-pathological characteristics in Eastern Morocco: series of 2260 cases. BMC Womens Health. 2017, 17:3. 10.1186\/s12905-016-0361-z","journal-title":"BMC Womens Health"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2023.11.016","article-title":"Early breast cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"35","author":"Loibl S","year":"2024","unstructured":"Loibl S, Andr\u00e9 F, Bachelot T, et al.. Early breast cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol. 2024, 35:159-82. 10.1016\/j.annonc.2023.11.016","journal-title":"Ann Oncol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.00435","article-title":"Standardized definitions for efficacy end points in neoadjuvant breast cancer clinical trials: NeoSTEEP","volume":"41","author":"Litton JK","year":"2023","unstructured":"Litton JK, Regan MM, Pusztai L, et al.. Standardized definitions for efficacy end points in neoadjuvant breast cancer clinical trials: NeoSTEEP. J Clin Oncol. 2023, 41:4433-42. 10.1200\/JCO.23.00435","journal-title":"J Clin Oncol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1111\/tbj.13864","article-title":"Pathologic evaluation of response to neoadjuvant therapy drives treatment changes and improves long-term outcomes for breast cancer patients","volume":"26","author":"Bossuyt V","year":"2020","unstructured":"Bossuyt V, Spring L. Pathologic evaluation of response to neoadjuvant therapy drives treatment changes and improves long-term outcomes for breast cancer patients. Breast J. 2020, 26:1189-98. 10.1111\/tbj.13864","journal-title":"Breast J"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.02241","article-title":"Pathologic complete response and individual patient prognosis after neoadjuvant chemotherapy plus anti-human epidermal growth factor receptor 2 therapy of human epidermal growth factor receptor 2-positive early breast cancer","volume":"41","author":"van Mackelenbergh MT","year":"2023","unstructured":"van Mackelenbergh MT, Loibl S, Untch M, et al.. Pathologic complete response and individual patient prognosis after neoadjuvant chemotherapy plus anti-human epidermal growth factor receptor 2 therapy of human epidermal growth factor receptor 2-positive early breast cancer. J Clin Oncol. 2023, 41:2998-3008. 10.1200\/JCO.22.02241","journal-title":"J Clin Oncol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-19-3492","article-title":"Pathologic complete response after neoadjuvant chemotherapy and impact on breast cancer recurrence and survival: a comprehensive meta-analysis","volume":"26","author":"Spring LM","year":"2020","unstructured":"Spring LM, Fell G, Arfe A, et al.. Pathologic complete response after neoadjuvant chemotherapy and impact on breast cancer recurrence and survival: a comprehensive meta-analysis. Clin Cancer Res. 2020, 26:2838-48. 10.1158\/1078-0432.CCR-19-3492","journal-title":"Clin Cancer Res"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-023-38200-y","article-title":"Predictive biological factors for late survival in patients with HER2-positive breast cancer","volume":"13","author":"Kang YJ","year":"2023","unstructured":"Kang YJ, Oh SJ, Bae SY, et al.. Predictive biological factors for late survival in patients with HER2-positive breast cancer. Sci Rep. 2023, 13:11008. 10.1038\/s41598-023-38200-y","journal-title":"Sci Rep"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14030534","article-title":"Racial\/ethnic differences and trends in pathologic complete response following neoadjuvant chemotherapy for breast cancer","volume":"14","author":"Ma SJ","year":"2022","unstructured":"Ma SJ, Serra LM, Yu B, et al.. Racial\/ethnic differences and trends in pathologic complete response following neoadjuvant chemotherapy for breast cancer. Cancers (Basel). 2022, 14:534. 10.3390\/cancers14030534","journal-title":"Cancers (Basel)"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.02309","article-title":"Estrogen and progesterone receptor testing in breast cancer: ASCO\/CAP guideline update","volume":"38","author":"Allison KH","year":"2020","unstructured":"Allison KH, Hammond ME, Dowsett M, et al.. Estrogen and progesterone receptor testing in breast cancer: ASCO\/CAP guideline update. J Clin Oncol. 2020, 38:1346-66. 10.1200\/JCO.19.02309","journal-title":"J Clin Oncol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.02864","article-title":"Human epidermal growth factor receptor 2 testing in breast cancer: ASCO-College of American Pathologists guideline update","volume":"41","author":"Wolff AC","year":"2023","unstructured":"Wolff AC, Somerfield MR, Dowsett M, et al.. Human epidermal growth factor receptor 2 testing in breast cancer: ASCO-College of American Pathologists guideline update. J Clin Oncol. 2023, 41:3867-72. 10.1200\/JCO.22.02864","journal-title":"J Clin Oncol"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-020-06090-7","article-title":"Effect of time to breast cancer surgery after neoadjuvant chemotherapy on survival outcomes","volume":"186","author":"Al-Masri M","year":"2021","unstructured":"Al-Masri M, Aljalabneh B, Al-Najjar H, Al-Shamaileh T. Effect of time to breast cancer surgery after neoadjuvant chemotherapy on survival outcomes. Breast Cancer Res Treat. 2021, 186:7-13. 10.1007\/s10549-020-06090-7","journal-title":"Breast Cancer Res Treat"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.02363","article-title":"Re-evaluation of pathologic complete response as a surrogate for event-free and overall survival in human epidermal growth factor receptor 2-positive, early breast cancer treated with neoadjuvant therapy including anti-human epidermal growth factor receptor 2 therapy","volume":"41","author":"Squifflet P","year":"2023","unstructured":"Squifflet P, Saad ED, Loibl S, et al.. Re-evaluation of pathologic complete response as a surrogate for event-free and overall survival in human epidermal growth factor receptor 2-positive, early breast cancer treated with neoadjuvant therapy including anti-human epidermal growth factor receptor 2 therapy. J Clin Oncol. 2023, 41:2988-97. 10.1200\/JCO.22.02363","journal-title":"J Clin Oncol"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1007\/s12094-025-03937-7","article-title":"Predictive factors for pCR and relapse following neoadjuvant dual HER2-blockade in HER2+ breast cancer: an international cohort study","volume":"27","author":"Luz P","year":"2025","unstructured":"Luz P, Lopes-Br\u00e1s R, de Pinho IS, et al.. Predictive factors for pCR and relapse following neoadjuvant dual HER2-blockade in HER2+ breast cancer: an international cohort study. Clin Transl Oncol. 2025, 27:4160-9. 10.1007\/s12094-025-03937-7","journal-title":"Clin Transl Oncol"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.3892\/ol.2023.14021","article-title":"Predictors of successful neoadjuvant treatment in HER2\u2011positive breast cancer","volume":"26","author":"H\u00e4nnik\u00e4inen EN","year":"2023","unstructured":"H\u00e4nnik\u00e4inen EN, Mattson J, Karihtala P. Predictors of successful neoadjuvant treatment in HER2\u2011positive breast cancer. Oncol Lett. 2023, 26:434. 10.3892\/ol.2023.14021","journal-title":"Oncol Lett"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30852-0","article-title":"Neoadjuvant and adjuvant trastuzumab in patients with HER2-positive locally advanced breast cancer (NOAH): follow-up of a randomised controlled superiority trial with a parallel HER2-negative cohort","volume":"15","author":"Gianni L","year":"2014","unstructured":"Gianni L, Eiermann W, Semiglazov V, et al.. Neoadjuvant and adjuvant trastuzumab in patients with HER2-positive locally advanced breast cancer (NOAH): follow-up of a randomised controlled superiority trial with a parallel HER2-negative cohort. Lancet Oncology. 2014, 15:640-7. 10.1016\/S1470-2045(18)30852-0","journal-title":"Lancet Oncology"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(11)70336-9","article-title":"Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial","volume":"13","author":"Gianni L","year":"2012","unstructured":"Gianni L, Pienkowski T, Im YH, et al.. Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial. Lancet Oncology. 2012, 13:25-32. 10.1016\/S1470-2045(11)70336-9","journal-title":"Lancet Oncology"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.99779","article-title":"Pathologic complete response rates in early-stage human epidermal growth factor 2 (HER2)-positive breast cancer treated with neoadjuvant chemotherapy and anti-HER2 therapy: a real-world experience","volume":"17","author":"Mokfi R","year":"2025","unstructured":"Mokfi R, Boutaagount F, Maskrout M, et al.. Pathologic complete response rates in early-stage human epidermal growth factor 2 (HER2)-positive breast cancer treated with neoadjuvant chemotherapy and anti-HER2 therapy: a real-world experience. Cureus. 2025, 17:e99779. 10.7759\/cureus.99779","journal-title":"Cureus"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdt182","article-title":"Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA)","volume":"24","author":"Schneeweiss A","year":"2013","unstructured":"Schneeweiss A, Chia S, Hickish T, et al.. Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA). Ann Oncol. 2013, 24:2278-84. 10.1093\/annonc\/mdt182","journal-title":"Ann Oncol"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30570-9","article-title":"Neoadjuvant chemotherapy with or without anthracyclines in the presence of dual HER2 blockade for HER2-positive breast cancer (TRAIN- 2): a multicentre, open-label, randomised, phase 3 trial","volume":"19","author":"van Ramshorst MS","year":"2018","unstructured":"van Ramshorst MS, van der Voort A, van Werkhoven ED, et al.. Neoadjuvant chemotherapy with or without anthracyclines in the presence of dual HER2 blockade for HER2-positive breast cancer (TRAIN- 2): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncology. 2018, 19:1630-40. 10.1016\/S1470-2045(18)30570-9","journal-title":"Lancet Oncology"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-021-06124-8","article-title":"Immunohistochemical HER2 score correlates with response to neoadjuvant chemotherapy in HER2-positive primary breast cancer","volume":"186","author":"Wang Y","year":"2021","unstructured":"Wang Y, Singh K, Dizon D, Graves T, Amin A, Yakirevich E. Immunohistochemical HER2 score correlates with response to neoadjuvant chemotherapy in HER2-positive primary breast cancer. Breast Cancer Res Treat. 2021, 186:667-76. 10.1007\/s10549-021-06124-8","journal-title":"Breast Cancer Res Treat"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1093\/oncolo\/oyae047","article-title":"Comparison of the response to neoadjuvant therapy between immunohistochemistry HER2 (3+) and HER2 (2+)\/ISH+ early-stage breast cancer: a retrospective multicenter cohort study","volume":"29","author":"Jiao D","year":"2024","unstructured":"Jiao D, Li G, Dai H, et al.. Comparison of the response to neoadjuvant therapy between immunohistochemistry HER2 (3+) and HER2 (2+)\/ISH+ early-stage breast cancer: a retrospective multicenter cohort study. Oncologist. 2024, 29:e877-86. 10.1093\/oncolo\/oyae047","journal-title":"Oncologist"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1016\/j.breast.2024.103733","article-title":"Distinct ER and PR expression patterns significantly affect the clinical outcomes of early HER2-positive breast cancer: a real-world analysis of 871 patients treated with neoadjuvant therapy","volume":"75","author":"Chen H","year":"2024","unstructured":"Chen H, Gui X, Zhou Z, et al.. Distinct ER and PR expression patterns significantly affect the clinical outcomes of early HER2-positive breast cancer: a real-world analysis of 871 patients treated with neoadjuvant therapy. Breast. 2024, 75:103733. 10.1016\/j.breast.2024.103733","journal-title":"Breast"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-19-2612","article-title":"What is the real impact of estrogen receptor status on the prognosis and treatment of HER2-positive early breast cancer?","volume":"26","author":"Brand\u00e3o M","year":"2020","unstructured":"Brand\u00e3o M, Caparica R, Malorni L, Prat A, Carey LA, Piccart M. What is the real impact of estrogen receptor status on the prognosis and treatment of HER2-positive early breast cancer?. Clin Cancer Res. 2020, 26:2783-8. 10.1158\/1078-0432.CCR-19-2612","journal-title":"Clin Cancer Res"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1016\/j.breast.2025.104454","article-title":"Influence of surgical timing post-neoadjuvant chemotherapy on survival outcomes in breast cancer patients: a comprehensive systematic review and meta-analysis","volume":"81","author":"Wang D","year":"2025","unstructured":"Wang D, Sun X, Sun W, Wang R, Pan H, Zhou W. Influence of surgical timing post-neoadjuvant chemotherapy on survival outcomes in breast cancer patients: a comprehensive systematic review and meta-analysis. Breast. 2025, 81:104454. 10.1016\/j.breast.2025.104454","journal-title":"Breast"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/502303-identifying-predictors-of-pathological-complete-response-in-moroccan-patients-with-her2-positive-breast-cancer-treated-with-neoadjuvant-therapy","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,5]],"date-time":"2026-07-05T20:56:55Z","timestamp":1783285015000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/502303-identifying-predictors-of-pathological-complete-response-in-moroccan-patients-with-her2-positive-breast-cancer-treated-with-neoadjuvant-therapy"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,5]]},"references-count":28,"URL":"https:\/\/doi.org\/10.7759\/cureus.112103","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7,5]]}}}